Stealth BioTherapeutics Corp

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome

STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

US FDA asks Stealth BioTherapeutics to resubmit application for rare genetic condition therapy

FDA delays decision on Stealth BioTherapeutics' rare genetic disorder drug

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome

STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION

Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference

STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series

Good Penny Stocks to Buy Today? 3 to Watch Right Now

Why Stealth BioTherapeutics Shares Are Surging Today?

What to Know About Buying Penny Stocks on May 10th

Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study

Stealth BioTherapeutics to Present at Upcoming March Investor Conferences

Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit

Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript

Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting